Polyneuron is a pharmaceutical company that is committed to the development of a new drug class for the treatment of antibody-mediated autoimmune diseases of the nervous system where a pathological role of anti-carbohydrate autoantibodies is well established. The Company’s Antibody-Catch™ technology platform enables the chemical design of injectable glycopolymers that are able to selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact.
|Employees (est.) (Jan 2021)||16|
Polyneuron total Funding
Polyneuron latest funding size
Time since last funding
|4 months ago|
|New Enterprise Associates, Sofinnova Partners, EVA Basel, Zürcher Kantonal Bank, HBM Healthcare Investments, Venture Kick|
Polyneuron has 249 Twitter Followers. The number of followers has increased 0.3% month over month and increased 3.5% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Polyneuron founded?
Polyneuron was founded in 2014.
Who are Polyneuron key executives?
Polyneuron's key executives are Ruben Herrendorff, Pascal Haenggi and Michael Wacker.
How many employees does Polyneuron have?
Polyneuron has 16 employees.
Who are Polyneuron competitors?
Competitors of Polyneuron include ReViral, Sosei Heptares and Seres Therapeutics.
Where is Polyneuron headquarters?
Polyneuron headquarters is located at Hochbergerstrasse 60C, Basel.
Where are Polyneuron offices?
Polyneuron has an office in Basel.
How many offices does Polyneuron have?
Polyneuron has 1 office.
Receive alerts for 300+ data fields across thousands of companies